Advanced search
Publication Cover
Journal of Dermatological Treatment Volume 34, 2023 - Issue 1
Submit an article Journal homepage
1,031
Views
0
CrossRef citations to date
0
Altmetric
Article

Effectiveness and safety of ustekinumab for the treatment of psoriasis; six years of clinical experience

Melis Gönülala Department of Dermatology, İzmir Tepecik Training and Research Hospital, University of Health Sciences, İzmir, Turkey;b İzmir Faculty of Medicine, Department of Dermatology, University of Health Sciences, İzmir, TurkeyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-4496-7769View further author information
ORCID Icon,
Didem Didar Balcıa Department of Dermatology, İzmir Tepecik Training and Research Hospital, University of Health Sciences, İzmir, TurkeyORCID Iconhttps://orcid.org/0000-0002-5012-4824View further author information
ORCID Icon,
Aylin Öztürkc Department of Dermatology, Ankara City Hospital, Ankara, TurkeyORCID Iconhttps://orcid.org/0000-0001-9224-0252View further author information
ORCID Icon &
Sinan Doğand Çiğli Regional Education Hospital, Department of Dermatology, Bakırçay University, İzmir, TurkeyORCID Iconhttps://orcid.org/0000-0001-5448-9671View further author information
ORCID Icon
Article: 2241941 | Received 01 Jun 2023, Accepted 25 Jul 2023, Published online: 02 Aug 2023

References

  • Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1–4. doi:10.1001/jama.2020.4006.
  • Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(2):205–212. doi:10.1111/jdv.13854.
  • Kamata M, Tada Y. Safety of biologics in psoriasis. J Dermatol. 2018;45(3):279–286. doi:10.1111/1346-8138.14096.
  • van Vollenhoven RF, Hahn BH, Tsokos GC, et al. Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study. Lancet. 2018;392(10155):1330–1339. doi:10.1016/S0140-6736(18)32167-6.
  • Leonardi CL, Kimball AB, Papp KA, et al.  Effi cacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1).  Lancet. 2008;371(9625):1665–1674. doi:10.1016/S0140-6736(08)60725-4.
  • Young MS, Horn EJ, Cather JC. The ACCEPT study: ustekinumab versus etanercept in moderate-to-severe psoriasis patients. Expert Rev Clin Immunol. 2011;7(1):9–13. doi:10.1586/eci.10.92.
  • Sbidian E, Chaimani A, Garcia-Doval I. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis (review). Cochrane Database Syst Rev. 2017;12(12):CD011535.
  • Schmitt J, Rosumeck S, Thomaschewski G, et al. Efficacy and safety of systemic treatments for moderateto-severe psoriasis: meta-analysis of randomized controlled trials. Br J Dermatol. 2014;170(2):274–303. doi:10.1111/bjd.12663.
  • Igarashi A, Kato T, Kato M, et al. Efficacy and safety of ustekinumab in Japanese patients with moderate-tosevere plaque-type psoriasis: long-term results from a phase 2/3 clinical trial. J Dermatol. 2012;39(3):242–252. doi:10.1111/j.1346-8138.2011.01347.x.
  • Gordon KB, Strober B, Lebwohl M, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018;392(10148):650–661. doi:10.1016/S0140-6736(18)31713-6.
  • Papp KA, Langley RG, Lebwohl M, et al. Effi cacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371:1665–1674.
  • Wang TS, Tsai TF. Biologics switch in psoriasis. Immunotherapy. 2019;11(6):531–541. doi:10.2217/imt-2018-0131.
  • Griffiths CE, Strober BE, Van de Kerkhof P, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med. 2010;362(2):118–128. doi:10.1056/NEJMoa0810652.
  • Tsai YC, Tsai TF. Switching biologics in psoriasis – practical guidance and evidence to support. Expert Rev Clin Pharmacol. 2020;13(5):493–503. doi:10.1080/17512433.2020.1767590.
  • Sbidian E, Chaimani A, Garcia-Doval I, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2022;5(5):CD011535.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.